Figure 2.

A. Chronic treatment schematic with timeline in days (left) and, on day-8, PET/CT imaging schematic with timeline in minutes (right). B. Daily treatment with Cpd-60 (22.5 mg/kg) or CI-994 (5 mg/kg) did not significantly affect rat weight over seven days compared to vehicle-treated controls (n=11–12/group). C. and E. Brain regions with significant changes in glucose uptake induced by chronic treatment with C. Cpd-60, an HDAC1,2 inhibitor or E. CI-994, an HDAC1,2,3 inhibitor. Brain structures abbreviated in upper left corner of each panel comprise significant increases (yellow/red t-value maps) and decreases (blue t-value maps) compared to vehicle treated controls (n=11–12/group). Anterior-Posterior distance from Bregma (mm) is indicated in lower right corner of each panel. D. and F. Histograms showing percent changes in local ¹⁸FDG uptake induced by treatment with Cpd-60 (D.) or CI-994 (F.) relative to controls. Changes were evaluated using ROI analysis of regions highlighted in C. and D. and including increases in ¹⁸FDG uptake (left of dashed lines) and decreases (right of dashed line).